ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NVAX Novavax Inc

4.33
0.03 (0.70%)
Apr 12 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,008,108
Bid Price 4.33
Ask Price 4.34
News -
Day High 4.4773

Low
3.5324

52 Week Range

High
11.36

Day Low 4.24
Company Name Stock Ticker Symbol Market Type
Novavax Inc NVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 0.70% 4.33 19:57:46
Open Price Low Price High Price Close Price Prev Close
4.30 4.24 4.4773 4.28 4.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,525 4,008,108 $ 4.35 $ 17,417,929 - 3.5324 - 11.36
Last Trade Time Type Quantity Stock Price Currency
19:59:31 2 $ 4.34 USD

Novavax (NVAX) Options Flow Summary

Overall Flow

Bearish

Net Premium

-4M

Calls / Puts

100.00%

Buys / Sells

300.00%

OTM / ITM

33.33%

Sweeps Ratio

0.25%

Novavax Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
599M 139.95M - 983.71M -545.06M -3.89 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Novavax News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NVAX Message Board. Create One! See More Posts on NVAX Message Board See More Message Board Posts

Historical NVAX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.394.654.224.353,503,295-0.06-1.37%
1 Month4.975.404.224.724,332,076-0.64-12.88%
3 Months4.116.053.53244.727,722,9450.225.35%
6 Months7.607.633.53245.217,646,344-3.27-43.03%
1 Year9.1511.363.53246.687,748,575-4.82-52.68%
3 Years182.65277.79993.532455.576,372,480-178.32-97.63%
5 Years11.58331.53883.532461.025,775,858-7.25-62.61%

Novavax Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Your Recent History

Delayed Upgrade Clock